Eli Lilly’s weight-loss drug Zepbound has emerged as the winner in its first head-to-head trial, with users losing 20% of their body weight over a 72-week period. In contrast, those who received Wegovy shed just 14%. The study’s findings reinforce earlier trials and suggest that Zepbound has a stronger impact on weight loss, offering new hope for the burgeoning market of obesity treatments.
Source: https://www.bloomberg.com/news/articles/2024-12-04/lilly-s-zepbound-beats-novo-s-wegovy-in-first-head-to-head-trial